

# Johanna C Kluin-Nelemans

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8434542/johanna-c-kluin-nelemans-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182  
papers

10,501  
citations

50  
h-index

99  
g-index

183  
ext. papers

11,918  
ext. citations

5.9  
avg, IF

5.35  
L-index

#	Paper	IF	Citations
182	A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <i>Blood</i> , <b>2008</b> , 111, 558-65	2.2	676
181	A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 850-8	9.7	610
180	Double-hit B-cell lymphomas. <i>Blood</i> , <b>2011</b> , 117, 2319-31	2.2	515
179	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. <i>Blood</i> , <b>2005</b> , 105, 2677-84	2.2	443
178	Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. <i>Blood</i> , <b>2001</b> , 97, 2549-54	2.2	379
177	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1916-27	59.2	324
176	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , <b>2001</b> , 98, 3074-81	2.2	275
175	High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4483-8	2.2	272
174	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2530-41	59.2	269
173	Involved-field radiotherapy for advanced Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2396-406	59.2	255
172	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , <b>1999</b> , 94, 1201-1208	2.2	243
171	Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1045-51	59.2	241
170	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 25-45	11.5	209
169	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , <b>2010</b> , 115, 3215-23	2.2	200
168	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1386-94	2.2	197
167	Response to interferon alfa-2b in a patient with systemic mastocytosis. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 619-23	59.2	192
166	Cladribine therapy for systemic mastocytosis. <i>Blood</i> , <b>2003</b> , 102, 4270-6	2.2	185

165	Combined-modality therapy for clinical stage I or II Hodgkin lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3128-35	2.2	180
164	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 950-8	4.5	174
163	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , <b>2017</b> , 77, 1261-1270	10.1	162
162	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , <b>2013</b> , 24, 561-76	10.3	162
161	Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. <i>Laboratory Investigation</i> , <b>2001</b> , 81, 419-26	5.9	139
160	Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4135-42	2.2	131
159	Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 107, 2912-9	2.2	115
158	Unique polycomb gene expression pattern in Hodgkin lymphoma and Hodgkin lymphoma-derived cell lines. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 873-81	5.8	113
157	Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1338-46	2.2	112
156	Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. <i>British Journal of Haematology</i> , <b>1988</b> , 70, 55-62	4.5	107
155	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1125-1133.e1	5.4	106
154	The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. <i>Blood</i> , <b>2004</b> , 104, 143-8	2.2	94
153	Cardiovascular disease after treatment for Hodgkin lymphoma: an analysis of nine collaborative EORTC-LYSA trials. <i>Lancet Haematology</i> , <b>2015</b> , 2, e492-502	14.6	90
152	High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 93-99	7	87
151	Gonadal function in males after chemotherapy for early-stage Hodgkin lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2825-32	2.2	81
150	Quality of life after successful treatment of early-stage Hodgkin lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1160-70	21.7	80
149	Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. <i>Journal of Immunology</i> , <b>2007</b> , 178, 2287-95	5.3	78
148	Premature ovarian failure and fertility in long-term survivors of Hodgkin lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 291-9	2.2	77

147	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , <b>1998</b> , 92, 2871-2878	2.2	77
146	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. <i>Blood</i> , <b>2005</b> , 105, 2916-23	2.2	75
145	Early onset post-transplant lymphoproliferative disease is associated with allograft localization. <i>Clinical Transplantation</i> , <b>2005</b> , 19, 327-34	3.8	75
144	In normal controls, both age and gender affect coagulability as measured by thrombelastography. <i>Anesthesia and Analgesia</i> , <b>2010</b> , 110, 987-94	3.9	73
143	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2007</b> , 33, 338-46	14.4	73
142	Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 125-30	11.5	65
141	Sperm quality before treatment in patients with early stage Hodgkin lymphoma enrolled in EORTC-GELA Lymphoma Group trials. <i>Haematologica</i> , <b>2009</b> , 94, 1691-7	6.6	63
140	Fertility preservation after chemotherapy for Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2010</b> , 28, 168-79	1.3	62
139	Identification of RUNX1/AML1 as a classical tumor suppressor gene. <i>Oncogene</i> , <b>2003</b> , 22, 538-47	9.2	61
138	Prevalence of indolent systemic mastocytosis in a Dutch region. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 1429-31.e1	11.5	57
137	High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 524-30	4.5	57
136	The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. <i>Human Immunology</i> , <b>2000</b> , 61, 565-74	2.3	57
135	The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. <i>Annals of Internal Medicine</i> , <b>2006</b> , 145, 807-15	8	55
134	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 52-6	4.5	53
133	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1348-1356	4.7	51
132	Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 489-96	4.5	47
131	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , <b>2016</b> , 101, 1133-1143	6.6	46
130	Haemostatic variables during normal menstrual cycle. A systematic review. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 22-9	7	45

129	IgD class switching: identification of a novel recombination site in neoplastic and normal B cells. <i>European Journal of Immunology</i> , <b>1995</b> , 25, 3504-8	6.1	45
128	Late non-neoplastic events in patients with aggressive non-Hodgkin lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 122-30		44
127	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , <b>2019</b> , 6, e638-e649	14.6	42
126	EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. <i>Blood</i> , <b>2008</b> , 112, 1039-41	2.2	41
125	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , <b>2020</b> , 10, 10743-10768	12.1	40
124	HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. <i>Transplantation</i> , <b>2005</b> , 80, 595-9	1.8	38
123	The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. <i>Thrombosis Research</i> , <b>2012</b> , 130, 334-8	8.2	37
122	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 526-32	1.9	36
121	Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. <i>Cancer</i> , <b>2000</b> , 89, 2667-76	6.4	36
120	Somatic pairing of centromeres and short arms of chromosome 15 in the hematopoietic and lymphoid system. <i>Human Genetics</i> , <b>1993</b> , 92, 577-82	6.3	35
119	Discordant morphologic characteristics of B-cell lymphomas in bone marrow and lymph node biopsies. <i>American Journal of Clinical Pathology</i> , <b>1990</b> , 94, 59-66	1.9	35
118	The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. <i>American Journal of Obstetrics and Gynecology</i> , <b>2013</b> , 209, 202.e1-7	6.4	33
117	Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 703-10	4.5	33
116	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 699-707	1.9	32
115	Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. <i>Blood</i> , <b>2004</b> , 103, 4408-15	2.2	31
114	Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. <i>Transplantation</i> , <b>2001</b> , 71, 47-52	1.8	31
113	Effects of red blood cells on hemostasis. <i>Transfusion</i> , <b>2010</b> , 50, 1536-44	2.9	29
112	Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 298-308	4.5	29

111	On the use of Cox regression in the presence of an irregularly observed time-dependent covariate. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 3817-29	2.3	29
110	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 248-256	2.2	29
109	Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. <i>Annals of Hematology</i> , <b>2005</b> , 84, 311-6	3	28
108	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 2226-36	1.9	27
107	Granulocytic sarcoma (chloroma). Presentation of an unusual case. <i>American Journal of Clinical Pathology</i> , <b>1991</b> , 95, 567-71	1.9	27
106	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , <b>2012</b> , 124, 807-14	2.3	26
105	Management around invasive procedures in mastocytosis: An update. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 119, 304-309	3.2	25
104	Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1006-1008.e7	11.5	24
103	Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 923-9	7	24
102	Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival. <i>Cancer</i> , <b>1997</b> , 79, 390-7	6.4	24
101	No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. <i>Leukemia Research</i> , <b>1984</b> , 8, 723-8	2.7	24
100	Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. <i>Blood Coagulation and Fibrinolysis</i> , <b>2010</b> , 21, 389-97	1	23
99	Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. <i>Blood</i> , <b>2008</b> , 111, 2581-8	2.2	23
98	Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3854-63	2.2	22
97	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , <b>1998</b> , 91, 4224-4231	2.2	22
96	Treatment of elderly patients with mantle cell lymphoma. <i>Seminars in Hematology</i> , <b>2011</b> , 48, 208-13	4	21
95	Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1176-83	11.5	21
94	Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin $\text{\textcircled{R}}$ lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3793-801	2.2	20

93	The European Competence Network on Mastocytosis (ECNM). <i>Wiener Klinische Wochenschrift</i> , <b>2004</b> , 116, 647-51	2.3	19
92	Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. <i>British Journal of Haematology</i> , <b>1989</b> , 72, 439-44	4.5	19
91	Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?. <i>Journal of Pathology</i> , <b>2015</b> , 236, 302-14	9.4	18
90	CD30 in systemic mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , <b>2014</b> , 34, 341-55	3.3	18
89	Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 1168-77	4	18
88	The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). <i>Blood</i> , <b>2010</b> , 116, 850-1	2.2	17
87	Haematopoietic and immunologic abnormalities in severe aplastic anaemia patients treated with anti-thymocyte globulin. <i>British Journal of Haematology</i> , <b>1989</b> , 71, 421-30	4.5	17
86	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , <b>2019</b> , 33, 1124-1134	10.7	17
85	Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 616-624	4.5	16
84	MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. <i>Histopathology</i> , <b>2017</b> , 71, 960-971	7.3	16
83	Active cytomegalovirus infection in patients with acute venous thrombosis: a case-control study. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 510-2	7.1	16
82	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , <b>2021</b> , 5, e646	0.3	16
81	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 300-306	11.5	15
80	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 356-366.e4	11.5	15
79	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1927-1938	9.3	15
78	Pain and anxiety during bone marrow biopsy. <i>Pain Management Nursing</i> , <b>2013</b> , 14, 310-317	2.5	15
77	Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. <i>Scandinavian Journal of Haematology</i> , <b>1986</b> , 36, 71-8		15
76	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , <b>2012</b> , 120, 799-799	2.2	15

75	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , <b>1999</b> , 93, 251-259	2.2	14
74	Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e120-e128	1.4	14
73	Lenalidomide therapy in systemic mastocytosis. <i>Leukemia Research</i> , <b>2009</b> , 33, e19-22	2.7	13
72	Characterisation of hairy cell leukaemia by tiling resolution array-based comparative genome hybridisation: a series of 13 cases and review of the literature. <i>European Journal of Haematology</i> , <b>2010</b> , 84, 17-25	3.8	13
71	Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. <i>Haematologica</i> , <b>2008</b> , 93, 120-3	6.6	13
70	Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-6	1.9	12
69	Low cut-off values increase diagnostic performance of protein S assays. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 618-25	7	12
68	Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non-Hodgkin lymphomas, according to data in the population-based registry of the Comprehensive Cancer Centre West. <i>Cancer</i> , <b>1998</b> , 83, 1612-9	6.4	12
67	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , <b>2014</b> , 124, 636-636	2.2	12
66	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , <b>2020</b> , 34, 1090-1101	10.7	12
65	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 242-6	1.9	11
64	Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. <i>Haematologica</i> , <b>2009</b> , 94, 1546-54	6.6	11
63	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7500-7500	2.2	11
62	Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149162	3.7	11
61	Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 667-71	4.5	10
60	Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 3256-60	4.3	10
59	Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 792-8	11.5	9
58	Interim thymus and activation regulated chemokine versus interim F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 40-44	4.5	9



57	Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 68-76	4.5	9
56	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , <b>2019</b> , 17, 115	3	9
55	Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 881-90	7	9
54	Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 216-22	4.5	9
53	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , <b>2013</b> , 8, 1229-36	4	9
52	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. <i>Thrombosis Research</i> , <b>2010</b> , 126, e249-54	8.2	9
51	Hairy Cell Leukemia and Its T Cell Interactions. <i>Leukemia and Lymphoma</i> , <b>1991</b> , 4, 159-66	1.9	9
50	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , <b>2021</b> , 11, 292-303	12.1	9
49	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3121-3127.e1	5.4	8
48	An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2008</b> , 74, 40-4	3.4	8
47	What is the optimal initial management of the older MCL patient?. <i>Best Practice and Research in Clinical Haematology</i> , <b>2018</b> , 31, 99-104	4.2	7
46	Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2016</b> , 9, 388-94	5.8	7
45	Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. <i>Thrombosis Research</i> , <b>2011</b> , 128, 501-2	8.2	7
44	Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 385-393	4.5	6
43	Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes. <i>PLoS ONE</i> , <b>2014</b> , 9, e86556	3.7	6
42	Routine evaluation and treatment of unexplained menorrhagia: do we consider haemostatic disorders?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2010</b> , 152, 191-4	2.4	6
41	No difference between cytochemical and immunological detection of myeloperoxidase in AML. <i>British Journal of Haematology</i> , <b>1990</b> , 75, 630-1	4.5	6
40	Clinical course and pathologic features of conjunctival non-Hodgkin lymphoma. A report of six cases. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>1990</b> , 228, 246-51	3.8	6

39	T-cell prolymphocytic leukemia with an unusual phenotype CD4+ CD8+. <i>Cancer</i> , <b>1987</b> , 60, 794-803	6.4	6
38	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , <b>2013</b> , 122, 106-106	2.2	6
37	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , <b>1999</b> , 94, 1201-1208	2.2	6
36	Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms. <i>Psycho-Oncology</i> , <b>2019</b> , 28, 830-838	3.9	6
35	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , <b>2021</b> , 8, e648-e657	14.6	6
34	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2018</b> , 36, 416-421	1.3	5
33	Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 240-7		5
32	Comparison between clonogenic and cytotoxic assays for measuring LAK cell activity. <i>International Journal of Cell Cloning</i> , <b>1989</b> , 7, 232-41		5
31	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
30	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,	5.4	5
29	No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. <i>Cancer Epidemiology</i> , <b>2017</b> , 48, 110-116	2.8	4
28	Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma [Results from Randomized Trials of the European MCL Network. <i>Blood</i> , <b>2014</b> , 124, 2977-2977	2.2	4
27	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 1719-1727	4.3	4
26	The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 150-160	7.5	4
25	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 487-498	5.4	4
24	Splenectomy and second malignancies in patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 230-1	1.9	3
23	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1705-1712.e4	5.4	3
22	PROS1 Heerlen polymorphism is associated with increased free plasma tissue factor pathway inhibitor levels. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 594-6	7	2

21	A Pre-induction course with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 275-7	4.5	2
20	The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6009-16	5.3	2
19	Mismatched transplants for refractory lymphoma?. <i>Lancet, The</i> , <b>1999</b> , 353, 1725-6	4.0	2
18	Characterization of a New Human B Cell Line (Bonna-12) with Trisomy 9 and Trisomy 12 Chromosomal Abnormality. <i>Leukemia and Lymphoma</i> , <b>1991</b> , 5, 415-22	1.9	2
17	High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin.. <i>Blood</i> , <b>2004</b> , 104, 19-19	2.2	2
16	Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma.. <i>Blood</i> , <b>2012</b> , 120, 2677-2677	2.2	2
15	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , <b>1998</b> , 92, 2871-2878	2.2	2
14	Correction of Abnormal T-Cell Receptor Repertoire During Interferon- $\gamma$ Therapy in Patients With Hairy Cell Leukemia. <i>Blood</i> , <b>1998</b> , 91, 4224-4231	2.2	2
13	Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 636-45	4.5	2
12	Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones. <i>Blood</i> , <b>1999</b> , 93, 251-259	2.2	1
11	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. <i>Blood</i> , <b>2021</b> , 137, 3251-3258	2.2	1
10	Autologous stem cell transplantation in treatment of aggressive non-Hodgkin lymphoma. <i>Croatian Medical Journal</i> , <b>2002</b> , 43, 561-4	1.6	1
9	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	1
8	Junior Scientific Masterclass: Additional Science Training for Medical Students. <i>Medical Science Educator</i> , <b>2011</b> , 21, 86-90	0.7	0
7	Late relapses in diffuse large B-cell lymphoma: where to move next?. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1005-1006	1.9	
6	Reply to Z. Blumenfeld. <i>Hematological Oncology</i> , <b>2011</b> , 29, 53-53	1.3	
5	Hereditary Protein S Type III Deficiency Is Not a Risk Factor for Venous and Arterial Thrombosis, in Contrast to Protein S Deficiency Type I. Results from a Family Cohort Study To Assess the Clinical Impact of a Laboratory Based Classification.. <i>Blood</i> , <b>2004</b> , 104, 1056-1056	2.2	
4	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.. <i>Blood</i> , <b>2005</b> , 106, 5389-5389	2.2	

- 3 Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma.. *Blood*, **2009**, 114, 2313-2313 2.2
- 2 Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. *Blood*, **2012**, 120, 3656-3656
- 1 Therapy for stage I aggressive non-Hodgkin lymphoma. *Croatian Medical Journal*, **2002**, 43, 546-9 1.6